English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/180689
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorBarbero, Nekanees_ES
dc.contributor.authorFernández-Santamaría, Rubénes_ES
dc.contributor.authorMayorga, Cristobalinaes_ES
dc.contributor.authorMartín-Serrano, Ángelaes_ES
dc.contributor.authorSalas, Maríaes_ES
dc.contributor.authorBogas, Gadores_ES
dc.contributor.authorNájera, Franciscoes_ES
dc.contributor.authorPérez-Sala, Doloreses_ES
dc.contributor.authorPérez-Inestrosa, Ezequieles_ES
dc.contributor.authorFernández, Tahiaes_ES
dc.contributor.authorMontañez, M. I.es_ES
dc.contributor.authorTorres, María J.es_ES
dc.identifier.citationAllergy Allergy 74:1490–1501 (2019)es_ES
dc.description12 p.-6 fig.-1 graf. abst.es_ES
dc.description.abstractBACKGROUND: Selective reactions to clavulanic acid (CLV) account for around 30% of immediate reactions after administration of amoxicillin-CLV. Currently, no immunoassay is available for detecting specific IgE to CLV, and its specific recognition in patients with immediate reactions has only been demonstrated by basophil activation testing, however with suboptimal sensitivity. The lack of knowledge regarding the structure of the drug that remains bound to proteins (antigenic determinant) is hampering the development of in vitro diagnostics. We aimed to identify the antigenic determinants of CLV as well as to evaluate their specific IgE recognition and potential role for diagnosis.es_ES
dc.description.abstractMETHODS: Based on complex CLV degradation mechanisms, we hypothesized the formation of two antigenic determinants for CLV, AD-I (N-protein, 3-oxopropanamide) and AD-II (N-protein, 3-aminopropanamide), and designed different synthetic analogs to each one. IgE recognition of these structures was evaluated in basophils from patients with selective reactions to CLV and tolerant subjects. In parallel, the CLV fragments bound to proteins were identified by proteomic approaches.es_ES
dc.description.abstractRESULTS: Two synthetic analogs of AD-I were found to activate basophils from allergic patients. This determinant was also detected bound to lysines 195 and 475 of CLV-treated human serum albumin. One of these analogs was able to activate basophils in 59% of patients whereas CLV only in 41%. Combining both results led to an increase in basophil activation in 69% of patients, and only in 12% of controls.es_ES
dc.description.abstractCONCLUSION: We have identified AD-I as one CLV antigenic determinant, which is the drug fragment that remains protein-bound.es_ES
dc.description.sponsorshipThe present study has been supported by Institute of Health “Carlos III” of the Ministry of Economy and Competitiveness (grants cofunded by European Regional Development Fund (ERDF): PI12/02529, PI15/01206, CP15/00103, RETICs RIRAAF RD12/0013/0001, RD12/0013/0003 and RD12/0013/0008, RETIC ARADYAL RD16/0006/0001, RD16/0006/0012 and RD16/0006/0021, Biobank Network RD09/0076/00112, and Biobank platform PT13/0010/0006) and by State Secretariat for Research, Development and Innovation of the Ministry of Economy and Competitiveness (grants cofunded by European Regional Development Fund (ERDF), “Una manera de hacer Europa”: MINECO SAF2012-36519, SAF2015-68590R, CTQ2013-41339P, and CTQ2016-75870P). Andalusian Regional Ministry of Economy and Knowledge (grants cofunded by European Regional Development Fund (ERDF), “Andalucía se mueve con Europa”: CTS-06603); Andalusian Regional Ministry Health (grants: PI-0699-2011, PI-0159-2013, PI-0179-2014, PI-0241-2016, and PI-0250-2016), Merck-Serono Research Grant from Fundación Salud 2000 and “Premio UNICAJA a la innovación en biomedicina y salud.” CM holds a “Nicolas Monardes” research contract by Andalusian Regional Ministry Health: C-0044-2012 SAS 2013. MIM holds a “Miguel Servet I” and GB holds a “Rio Hortega,” both research contracts by Institute of Health “Carlos III” of the Ministry of Economy and Competitiveness (grants cofunded by European Social Fund (ESF)): CP15/00103 and CM16/00067. TDF hold a “Ramon y Cajal” research contract from Ministry of Economy and Competitiveness (RYC-2013-13138).es_ES
dc.publisherJohn Wiley & Sonses_ES
dc.subjectClavulanic acides_ES
dc.subjectDrug allergyes_ES
dc.subjectImmediate reactionses_ES
dc.subjectIn vitro testes_ES
dc.titleIdentification of an antigenic determinant of clavulanic acid responsible for IgE-mediated reactionses_ES
dc.description.peerreviewedPeer reviewedes_ES
dc.contributor.funderInstituto de Salud Carlos IIIes_ES
dc.contributor.funderMinisterio de Economía y Competitividad (España)es_ES
dc.contributor.funderJunta de Andalucíaes_ES
oprm.item.hasRevisionno ko 0 false*
dc.contributor.orcidMayorga, Cristobalina [0000-0001-8852-8077]es_ES
dc.contributor.orcidMartín-Serrano, Ángela [0000-0002-2908-8910]es_ES
dc.contributor.orcidNájera, Francisco [0000-0002-1635-5514]es_ES
dc.contributor.orcidSalas, María [0000-0002-0583-9492]es_ES
dc.contributor.orcidPérez-Sala, Dolores [0000-0003-0600-665X]es_ES
dc.contributor.orcidPérez-Inestrosa, Ezequiel [0000-0001-7546-5273]es_ES
dc.contributor.orcidFernández, Tahia [0000-0003-0625-2156]es_ES
dc.contributor.orcidMontañez, M. I. [0000-0001-6641-5979]es_ES
dc.contributor.orcidTorres, María J. [0000-0003-4499-840X]es_ES
Appears in Collections:(CIB) Artículos
Files in This Item:
File Description SizeFormat 
restringido.pdfRestringido20,59 kBAdobe PDFThumbnail
Show simple item record

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.